{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:40:28Z","timestamp":1790800828884,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jcehepatology.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jceh.2024.101345","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:34:19Z","timestamp":1706142859000},"page":"101345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Basics and Art of Immunosuppression in Liver Transplantation"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-3727","authenticated-orcid":false,"given":"Shekhar","family":"Poudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-7140","authenticated-orcid":false,"given":"Sanjiv","family":"Saigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2024.101345_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1590\/S1679-45082015RW3164","article-title":"Liver transplantation: history, outcomes and perspectives","volume":"13","author":"Meirelles J\u00fanior","year":"2015","journal-title":"Einstein (Sao Paulo)."},{"key":"10.1016\/j.jceh.2024.101345_bib2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamasurg.2022.3327","article-title":"Survival benefit of living-donor liver transplant","volume":"157","author":"Jackson","year":"2022","journal-title":"JAMA Surgery"},{"key":"10.1016\/j.jceh.2024.101345_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0000000000002650","article-title":"No gains in long-term survival after liver transplantation over the past three decades","volume":"269","author":"Rana","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.jceh.2024.101345_bib4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/lt.20137","article-title":"Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database","volume":"10","author":"Roberts","year":"2004","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5005\/jp-journals-10018-1301","article-title":"Update on immunosuppression in liver transplantation","volume":"9","author":"Tasdogan","year":"2019","journal-title":"Euroasian J Hepato-Gastroenterol"},{"key":"10.1016\/j.jceh.2024.101345_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1615\/CritRevEukaryotGeneExpr.2015011421","article-title":"Current state of immunosuppression: past, present, and future","volume":"25","author":"Karam","year":"2015","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.jceh.2024.101345_bib7","first-page":"108","article-title":"Immunosuppressive agents in organ transplantation: past, present, and future","volume":"20","author":"Hong","year":"2000","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jceh.2024.101345_bib8","article-title":"Classic and current opinions in human organ and tissue transplantation","volume":"14","author":"Oli","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jceh.2024.101345_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrgastro.2013.88","article-title":"Liver transplantation: past, present and future","volume":"10","author":"Zarrinpar","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib10","article-title":"An overview of immunosuppression in solid organ transplantation","volume":"21","author":"Cher Enderby","year":"2015","journal-title":"AJMC"},{"key":"10.1016\/j.jceh.2024.101345_bib11","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jceh.2022.06.007","article-title":"Immunosuppressive drugs in liver transplant: an insight","volume":"12","author":"Panackel","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib13","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3389\/fimmu.2020.02155","article-title":"The immunological basis of liver allograft rejection","volume":"11","author":"Ronca","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2024.101345_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jceh.2013.04.005","article-title":"Current status of immunosuppression in liver transplantation","volume":"3","author":"Choudhary","year":"2013","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib15","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJM198910193211606","article-title":"Liver transplantation (2)","volume":"321","author":"Starzl","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2024.101345_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cld.2016.12.007","article-title":"Management of immunosuppression in liver transplantation","volume":"21","author":"Dhanasekaran","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/jlts.2001.26353","article-title":"Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial","volume":"7","author":"Eason","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1128\/MCB.24.1.164-171.2003","article-title":"CD3\/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1","volume":"24","author":"Wang","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jceh.2024.101345_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nature03843","article-title":"T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand","volume":"436","author":"Choudhuri","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jceh.2024.101345_bib20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A\u00a0comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"6 suppl 3","key":"10.1016\/j.jceh.2024.101345_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0049-0172(92)90009-3","article-title":"Mechanisms of action of cyclosporine and effects on connective tissues","volume":"21","author":"Russell","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jceh.2024.101345_bib22","article-title":"Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners\u2019 understanding and offer strategies for educating patients and promoting adherence","volume":"19","author":"Vicari-Christensen","year":"2009","journal-title":"Prog Transplant (Aliso Viejo, Calif)"},{"key":"10.1016\/j.jceh.2024.101345_bib23","first-page":"38","article-title":"Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months","author":"Ramirez","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2024.101345_bib24","article-title":"The role of mTOR inhibitors in liver transplantation: reviewing the evidence","volume":"2014","author":"Klintmalm","year":"2014","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1399-3062.2009.00407.x","article-title":"Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity","volume":"11","author":"Ritter","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib26","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.10.059","article-title":"Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs","volume":"140","author":"S\u00e1nchez\u2013Fueyo","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2024.101345_bib27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.tp.0000234905.56926.7f","article-title":"Induction immunosuppression","volume":"82","author":"Kirk","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/lt.24323","article-title":"Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease","volume":"22","author":"Krishnamoorthy","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5500\/wjt.v12.i3.59","article-title":"Autoimmune hepatitis and liver transplantation: Indications, and recurrent and de novo autoimmune hepatitis","volume":"12","author":"Harputluoglu","year":"2022","journal-title":"World J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.22410","article-title":"Present state of immunosuppressive therapy in liver transplant recipients","volume":"17","author":"Wiesner","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib31","doi-asserted-by":"crossref","DOI":"10.21037\/amj.2018.01.07","article-title":"Immunosuppressive pharmacotherapy in liver transplantation","volume":"3","author":"Hussaini","year":"2018","journal-title":"AME Med J"},{"key":"10.1016\/j.jceh.2024.101345_bib32","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4254\/wjh.v7.i10.1355","article-title":"Review on immunosuppression in liver transplantation","volume":"7","author":"Moini","year":"2015","journal-title":"WJH"},{"key":"10.1016\/j.jceh.2024.101345_bib33","first-page":"CD005161","article-title":"Cyclosporin versus tacrolimus for liver transplanted patients","volume":"2006","author":"Haddad","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jceh.2024.101345_bib34","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(02)11196-2","article-title":"Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial","volume":"360","author":"O'Grady","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2024.101345_bib35","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3748\/wjg.15.4225","article-title":"Overview of immunosuppression in liver transplantation","volume":"15","author":"Pillai","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2024.101345_bib36","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/MOT.0000000000000387","article-title":"Once-daily tacrolimus in liver transplantation: a \u201cme-too drug\u201d, or a therapeutic advantage","volume":"22","author":"Trune\u010dka","year":"2017","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/lt.20112","article-title":"C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective","volume":"10","author":"Villamil","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib39","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1600-6143.2009.02705.x","article-title":"Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil","volume":"9","author":"Germani","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/jlts.2001.23356","article-title":"A\u00a0randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","article-title":"Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update","volume":"88","author":"Staatz","year":"2014","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jceh.2024.101345_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","article-title":"Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes","volume":"32","author":"Parfitt","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jceh.2024.101345_bib43","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.transproceed.2010.08.066","article-title":"Patterns of injury in mycophenolate mofetil-related colitis","volume":"42","author":"Al-Absi","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2024.101345_bib44","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2024.101345_bib45","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/jlts.2001.26510","article-title":"Orthotopic liver transplantation using low-dose tacrolimus and sirolimus","volume":"7","author":"McAlister","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2011.06.012","article-title":"The use of sirolimus should be restricted in liver transplantation","volume":"56","author":"Massoud","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1432-2277.2009.00969.x","article-title":"Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients","volume":"23","author":"Molinari","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.jceh.2024.101345_bib48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/jlts.2003.50079","article-title":"Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications","volume":"9","author":"Dunkelberg","year":"2003","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/lt.22441","article-title":"Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"18","author":"Liang","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib50","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1016\/j.transproceed.2014.08.045","article-title":"Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series","volume":"46","author":"Ferreiro","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2024.101345_bib51","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/ajt.14948","article-title":"De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: a trial-based linkage study","volume":"18","author":"Ying","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib52","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib53","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis","volume":"17","author":"Saliba","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib54","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A\u00a0randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation\u2013PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1600-6143.2011.03919.x","article-title":"Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial","volume":"12","author":"Abdelmalek","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib56","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.transproceed.2009.03.093","article-title":"Posttransplant proteinuria associated with everolimus","volume":"41","author":"Bertoni","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2024.101345_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jss.2009.07.013","article-title":"Everolimus interferes with the inflammatory phase of healing in experimental colonic anastomoses","volume":"167","author":"K\u00fcper","year":"2011","journal-title":"J Surg Res"},{"key":"10.1016\/j.jceh.2024.101345_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.685176","article-title":"Real-life experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant","volume":"12","author":"Sung","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jceh.2024.101345_bib59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/ijot.ijot_25_18","article-title":"Modulation of maintenance immunosuppression during infection in renal transplant recipients","volume":"12","author":"Fernando","year":"2018","journal-title":"Indian J Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2024.101345_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2009.209056w","article-title":"PTU-063 Effect of intra-operative methylprednisolone on post liver transplant intensive care unit course: further evidence for the existence of hepato-adrenal syndrome?","volume":"59","author":"Broomhead","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2024.101345_bib61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.2008.163527","article-title":"Immunosuppression for liver transplantation","volume":"58","author":"Geissler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2024.101345_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"4 suppl 1","key":"10.1016\/j.jceh.2024.101345_bib63","first-page":"S64","article-title":"Use of antilymphocyte induction therapy in liver transplantation","volume":"5","author":"Wall","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.jceh.2024.101345_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0165-2478(91)90206-P","article-title":"A\u00a0critical review of immunosuppressive therapy","volume":"29","author":"Briggs","year":"1991","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jceh.2024.101345_bib65","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.transproceed.2012.03.027","article-title":"Immunomodulation of human CD8+ T cells by thymoglobulin in\u00a0vitro","volume":"44","author":"Yu","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2024.101345_bib66","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/01.TP.0000062834.30922.FE","article-title":"Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy","volume":"75","author":"Eason","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib67","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/TP.0000000000000477","article-title":"Steroid-free liver transplantation using rabbit antithymocyte globulin induction in 500 consecutive patients","volume":"99","author":"Yoo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib69","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2009.07972.x","article-title":"Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia","volume":"148","author":"Anoop","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jceh.2024.101345_bib70","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1399-0012.2008.00816.x","article-title":"Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab","volume":"22","author":"Alcaide","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0009-9236(98)90024-8","article-title":"Disposition and immunodynamics of basiliximab in liver allograft recipients","volume":"64","author":"Kovarik","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jceh.2024.101345_bib72","series-title":"EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders","year":"2018"},{"key":"10.1016\/j.jceh.2024.101345_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1499-3872(16)60183-2","article-title":"Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials","volume":"16","author":"Zhang","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jceh.2024.101345_bib74","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5604\/01.3001.0012.2246","article-title":"Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: a single center study","volume":"19","author":"Hashim","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib75","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/TP.0b013e3181ff87cd","article-title":"Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies","volume":"90","author":"Larsen","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib76","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients","volume":"90","author":"Griny\u00f3","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib77","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/ijot.ijot_3_18","article-title":"Liver transplant pathology: when the things are grave","volume":"12","author":"Bansal","year":"2018","journal-title":"Indian J Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib79","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jceh.2017.10.003","article-title":"Acute and chronic rejection after liver transplantation: what a clinician needs to know","volume":"7","author":"Choudhary","year":"2017","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.jceh.2024.101345_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s43066-022-00170-7","article-title":"Late acute cellular rejection after switch to everolimus monotherapy at 11 months following liver transplantation","volume":"12","author":"Razafindrazoto","year":"2022","journal-title":"Egyptian Liver Journal"},{"key":"10.1016\/j.jceh.2024.101345_bib81","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.3748\/wjg.v27.i45.7771","article-title":"Chronic rejection after liver transplantation: opening the Pandora's box","volume":"27","author":"Angelico","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2024.101345_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cld.871","article-title":"Donor-specific antibodies in liver transplantation","volume":"15","author":"Nilles","year":"2020","journal-title":"Clin Liver Disease"},{"key":"10.1016\/j.jceh.2024.101345_bib83","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1097\/TXD.0000000000001080","article-title":"Treatment of chronic active antibody-mediated rejection with pulse steroids, IVIG, with or without rituximab is associated with increased risk of pneumonia","volume":"7","author":"Joachim","year":"2020","journal-title":"Transplantation Direct"},{"key":"10.1016\/j.jceh.2024.101345_bib84","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2021.07.027","article-title":"Antibody-mediated rejection of the liver allograft: an update and a clinico-pathological perspective","volume":"75","author":"Lee","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/TP.0000000000004250","article-title":"Current status of ABO-incompatible liver transplantation","volume":"107","author":"Egawa","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-6143.2005.01187.x","article-title":"The art and science of immunosuppression: the fifth annual american society of transplant surgeon's state-of-the-art winter symposium","volume":"6","author":"Pomfret","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib87","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.2174\/1381612826666200521142448","article-title":"Immunosuppression in kidney transplantation: state of the art and current protocols","volume":"26","author":"Bauer","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jceh.2024.101345_bib88","doi-asserted-by":"crossref","first-page":"333ra49","DOI":"10.1126\/scitranslmed.aac5954","article-title":"Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform","volume":"8","author":"Zarrinpar","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jceh.2024.101345_bib89","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00007890-201211271-01466","article-title":"Personalized pharmacotherpy after liver transplantation - the GRAFTT trial to Control tacrolimus dosing: 2375","volume":"94","author":"Lock","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00007890-199401000-00023","article-title":"Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation","volume":"57","author":"Ma\u00f1ez","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/lt.21397","article-title":"Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children","volume":"14","author":"Gras","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant Rev"},{"key":"10.1016\/j.jceh.2024.101345_bib93","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1097\/TXD.0000000000001159","article-title":"Renal protective effect of everolimus in liver transplantation: a prospective randomized open-label trial","volume":"7","author":"Kadry","year":"2021","journal-title":"Transplant Direct"},{"key":"10.1016\/j.jceh.2024.101345_bib94","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1248\/bpb.b20-00256","article-title":"Evaluation of proteinuria using urine protein: creatine ratio in treatment with molecular targeted agents for advanced renal cell carcinoma","volume":"43","author":"Nakamura","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jceh.2024.101345_bib95","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cld.817","article-title":"Does the liver provide immunosuppressive advantage?","volume":"13","author":"Levitsky","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib96","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/01.tp.0000176483.52769.5a","article-title":"Marked differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients","volume":"80","author":"Liu","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-6143.2008.02487.x","article-title":"Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation","volume":"9","author":"Shaked","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib98","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/ajt.13757","article-title":"Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients","volume":"16","author":"Levitsky","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib99","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jceh.2015.11.001","article-title":"Liver transplantation in India: at the crossroads","volume":"5","author":"Nagral","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12664-011-0138-0","article-title":"Cost and efficacy of immunosuppression using generic products following living donor liver transplantation in India","volume":"31","author":"Sudhindran","year":"2012","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2024.101345_bib101","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/cid\/ciw295","article-title":"Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis","volume":"63","author":"Donnelly","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib102","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12930","article-title":"Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection","volume":"20","author":"Bartoletti","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13134","article-title":"Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey","volume":"21","author":"Shepshelovich","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jceh.2024.101345_bib104","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib105","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/tri.12118","article-title":"Long-term outcome of \u2018long-term liver transplant survivors","volume":"26","author":"Rub\u00edn","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.jceh.2024.101345_bib106","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib107","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/cancers13071617","article-title":"Minimization of immunosuppressive therapy is associated with improved survival of liver transplant patients with recurrent hepatocellular carcinoma","volume":"13","author":"Ossami Saidy","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jceh.2024.101345_bib108","doi-asserted-by":"crossref","DOI":"10.21037\/tgh.2017.08.07","article-title":"Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?","volume":"2","author":"Angelico","year":"2017","journal-title":"Trans Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib109","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3389\/fimmu.2020.01044","article-title":"Transplant tolerance induction: Insights from the liver","volume":"11","author":"Dai","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2024.101345_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100760","article-title":"Immunotolerance in liver transplantation: a primer for the clinician","volume":"28","author":"P\u00e9rez-Escobar","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2024.101345_bib111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.2011.2014","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants","volume":"307","author":"Feng","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jceh.2024.101345_bib112","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/ajt.15205","article-title":"Outcomes of immunosuppression minimization and withdrawal early after liver transplantation","volume":"19","author":"Shaked","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib113","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1499-3872(13)60002-8","article-title":"Clinical operational tolerance in liver transplantation: state-of-the-art perspective and future prospects","volume":"12","author":"Liu","year":"2013","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jceh.2024.101345_bib114","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1097\/TP.0b013e3182003db7","article-title":"Long-term follow-up of 23 operational tolerant liver transplant recipients","volume":"90","author":"Tryphonopoulos","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib115","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/lt.23481","article-title":"Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance","volume":"18","author":"Demetris","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib116","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.humimm.2018.02.010","article-title":"Biomarkers of immune tolerance in liver transplantation","volume":"79","author":"Vionnet","year":"2018","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jceh.2024.101345_bib117","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/TP.0b013e318188d3e6","article-title":"FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal","volume":"86","author":"Pons","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101345_bib118","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21926\/obm.transplant.1903080","article-title":"Induction of tolerance towards solid organ allografts using hematopoietic cell transplantation in large animal models","volume":"3","author":"Graves","year":"2018","journal-title":"OBM Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib119","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/transplantology2040042","article-title":"Strategies to improve immune suppression post-liver transplantation: a review","volume":"2","author":"Mohamed","year":"2021","journal-title":"Transplantology"},{"key":"10.1016\/j.jceh.2024.101345_bib120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3389\/fimmu.2020.01326","article-title":"Progress in liver transplant tolerance and tolerance-inducing cellular therapies","volume":"11","author":"Du","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2024.101345_bib121","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.182.2.379","article-title":"Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte\/macrophage colony-stimulating factor","volume":"182","author":"Lu","year":"1995","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jceh.2024.101345_bib122","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/lt.24394","article-title":"Liver transplantation in the mouse: insights into liver immunobiology, tissue injury and allograft tolerance","volume":"22","author":"Yokota","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jceh.2024.101345_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2021.834645","article-title":"Editorial: artificial intelligence for precision medicine","volume":"4","author":"Deng","year":"2022","journal-title":"Front Artif Intell"},{"key":"10.1016\/j.jceh.2024.101345_bib124","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.15351","article-title":"Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers","volume":"19","author":"Reeve","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2024.101345_bib125","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ekir.2020.07.023","article-title":"Peripheral blood RNA sequencing unravels a differential signature of coding and noncoding genes by types of kidney allograft rejection","volume":"5","author":"Pineda","year":"2020","journal-title":"Kidney International Reports"},{"key":"10.1016\/j.jceh.2024.101345_bib126","unstructured":"Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial. ATC Abstracts."},{"key":"10.1016\/j.jceh.2024.101345_bib127","first-page":"265","article-title":"Artificial intelligence and personalized medicine","volume":"vol. 178","author":"Schork","year":"2019"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688324000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688324000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T21:13:39Z","timestamp":1715721219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688324000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0973688324000021"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2024.101345","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Basics and Art of Immunosuppression in Liver Transplantation","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2024.101345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101345"}}